MétaCan
Menu
Back to cohort

Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.

2016· article· en· W2724509358 on OpenAlexaff
Virginia F. Borges, Cristiano Ferrario, Nathalie Aucoin, Carla I. Falkson, Qamar J. Khan, Ian E. Krop, Stephen Welch, Philippe L. Bédard, Alison Conlin, Jorge Chaves, Luke Walker, Erika Hamilton

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsPrincess Margaret Cancer CentreCancer Care OntarioJewish General Hospital
Fundersnot available
KeywordsMedicineInternal medicineTaxanePertuzumabOncologyMetastatic breast cancerTrastuzumabBreast cancerCancer

Abstract

fetched live from OpenAlex

513 Background: Modern registry data of MBC (Hurvitz ‘15; Witzel ‘15) suggest that HER2+ pts with CNS metastases (CNS+) have a poor prognosis. CNS disease is also associated with worse PS & QOL scores. Most systemic treatments for MBC have limited brain penetration & clinical trials often exclude CNS+ pts, causing a lack of prospective data on the outcome of CNS+ pts treated (tx) in the post-pertuzumab (P) / T-DM1 era. We report here the efficacy results of CNS+ & CNS- pts tx at the RP2D of TDM1 & ONT-380, a HER2 selective TKI with CNS penetration. Methods: Study ONT-380-004, a Phase 1b study of T-DM1 & escalating doses of ONT-380, enrolled HER2+ MBC pts, including pts with previously tx CNS lesions (stable or progressive) or untreated asymptomatic CNS lesions. We report the efficacy results in all pts tx at the RP2D of ONT-380 (300 mg BID) & TDM1 (3.6 mg/kg IV q 21 days) tx before 6/15/15. Eligibility: HER2+ MBC post taxane/trastuzumab (T); RECIST 1.1 measurable or non-measurable disease. All pts had baseline scans (including brain MRI). Efficacy assessments q6w x 6m, then q9w: OR & PFS by RECIST 1.1; CNS by modified CNS RECIST 1.1. Results: 45 pts were tx at the RP2D including 26 CNS+ (58%), the majority of whom were either progressing post-CNS treatment or had untreated CNS mets. Median age 51 y, 69% ER+, 31% ER-, 47% PS 0, 53% PS 1. Median 2 prior metastatic regimens: 100% taxane/T, 44% prior P, 22% prior lapatinib (L). In evaluable pts, OR was 47% (15/32) & was similar in CNS+ & CNS- pts: 47% (9/19) vs. 46% (6/13). Of the 26 CNS+ pts, 12 had measurable CNS mets, with best CNS response: 2 CRs, 2 PRs, 5 SDs (3/5 SD > 6m), 2 PDs, 1 NE. Median PFS overall was 6.5 m: CNS+ median PFS 6.5 m, & in the subset of CNS+ pts w progressing lesions post-tx or asymptomatic untx metastases, the median PFS was 6.7 m. The median PFS for CNS- was 8.2 m. The safety profile in CNS+ & CNS- pts was similar & unchanged from SABCS ’15; a complete safety update will be presented at ASCO. Conclusions: In a poor-prognosis HER2+ population with many CNS+ pts & with prior exposure to P or L, ONT-380 given in combination with T-DM1 resulted in promising PFS & ORR in both CNS- & CNS+ pts, with evidence of sustained CNS responses. Clinical trial information: NCT02025192.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.318
Threshold uncertainty score0.522

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0050.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.119
GPT teacher head0.473
Teacher spread0.354 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations31
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicBrain Metastases and TreatmentFrench-language works237,207